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Recent work by Rosenberg, et. al. demonstrates the role
of mutated epitopes in natural anti-cancer adaptive
immunity. This has led some to hypothesize that cancer
vaccines may need to induce or augment immunity
against mutated and potentially patient-specific epitopes
to achieve therapeutic efficacy. In the case of whole-cell
cancer vaccines, this could happen either indirectly
through epitope spreading, or directly against ‘hotspot’
mutation sites on oncogenes. The purpose of this study
is to determine whether patients who received an irra-
diated GM-CSF-secreting whole-cell prostate cancer
vaccine, GVAX, preferentially developed humoral
immune responses against mutated proteins. Archived
pre-treatment and week 11 serum from patients enrolled
on an investigator-initiated combination immunotherapy
trial were assessed using protein arrays (ProtoArray,
Invitrogen). Antibody responses that were increased in
the week 11 sera were considered increased as a result
of immunotherapy. Next we utilized reported liquid
chromatography tandem mass spectrometry (LC-MS/
MS) proteomics and whole-exome sequencing data for
LNCaP and PC3, the two cell lines contained in prostate
GVAX, to assess whether the targets of elevated anti-
body responses detected by protein array were directed
preferentially against the mutated proteins contained in
the vaccine. Of the 7554 different human proteins
included in our analysis, a mean of 63 candidate respon-
ses were identified for each patient (SD = 43). These
candidate responses were then compared to published
non-synonymous mutations in LNCaP and PC3, published
LC-MS/MS proteomics on the protein content of LNCaP
and PC3, and randomized lists of proteins on the array
[1-3]. Preliminary analysis suggests that there was no
increase in antibody responses above background against
proteins with published cell-line specific mutations.
However, the number of antibody responses was increased
against proteins identified by mass spectrometry
(p = 0.017). This result suggests that when GM-CSF
secreting whole-cell vaccine is not combined with other
immunotherapies, vaccine alone may be insufficient to
induce or augment immune responses against mutated
epitopes.
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